We are studying the safety and effectiveness of a new treatment combining VB10.16 with pembrolizumab for patients with HPV16-positive head and neck cancer. This trial aims to find the best dose and evaluate how well this combination works against the cancer.
Health conditions and diseases that the clinical trial is designed to study and treat.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a type of cancer that arises in the squamous cells lining the head and neck, often linked to HPV infection, particularly HPV16. This condition can be recurrent or metastatic, meaning it may return after treatment or spread to other parts of the body.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
